Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.

World journal of gastroenterology - 14 Dec 2016

Xie Yuan, Jiang Yan, Yang Xiao-Bo, Wang An-Qiang, Zheng Yong-Chang, Wan Xue-Shuai, Sang Xin-Ting, Wang Kai, Zhang Da-Dong, Xu Jia-Jia, Li Fu-Gen, Zhao Hai-Tao

Abstract excerpt

Gallbladder cancer (GBC), although considered as a relatively rare malignancy, is the most common neoplasm of the biliary tract system. The late diagnosis and abysmal prognosis present challenges to treatment. The overall 5-year survival rate for metastatic GBC patients is extremely low. BRCA1 and BRCA2 are the breast cancer susceptibility genes and their mutation carriers are at a high risk for cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Gallbladder Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Liver Neoplasms

Share to Phthalazines

Share to Piperazines

Share to Tomography, X-Ray Computed

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 28028375
DOI: 10.3748/wjg.v22.i46.10254
PMCID: PMC5155186

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report.PMID 28028375Read ↗

Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation.Semantic proximity Read ↗

Gallbladder cancer in Chile: what have we learned?Semantic proximity Read ↗

Targeting BRCA-mutant biliary tract cancer: Current evidence and future perspectives.Semantic proximity Read ↗

Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature.Semantic proximity Read ↗

Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case reportSemantic proximity Read ↗

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.Semantic proximity Read ↗

Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.Semantic proximity Read ↗

Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation.Semantic proximity Read ↗

A case of unresectable intrahepatic cholangiocarcinoma with a germline BRCA1 mutation.Semantic proximity Read ↗

Exceptional Response to Olaparib: A Case Report of Metastatic Esophageal Squamous Cell Carcinoma in a Patient With Fanconi Anemia, Germline FANCA Mutation, and Somatic BRCA2 Mutations.Semantic proximity Read ↗

Aspects on gallbladder cancer in 2014.Semantic proximity Read ↗

Death receptor (DR4) haplotypes are associated with increased susceptibility of gallbladder carcinoma in north Indian population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.